Treo Ventures is a Santa Clara-based venture capital firm with offices in Dublin that focuses on medical device and digital health companies. It typically invests at Series A and B and emphasizes demonstrated efficacy and clinical validation. That gives it a more evidence-driven and later-oriented profile than many seed-focused neurotech investors.

Its investment model is especially aligned with regulated medtech and neurodevice companies that have moved beyond prototype and are building toward FDA or CE-mark pathways. Treo is less about funding raw frontier science and more about backing companies that can show practical clinical proof and commercial potential. That can make it a strong partner for founders entering the more execution-heavy stages of device development.

The firm invests across the United States and Europe. For neurotech founders, Treo is especially relevant to clinical-stage neurodevice and digital health companies with strong validation data. It is a solid transatlantic partner for founders building evidence-backed medical technologies.